OECD Book: Innovation in Pharmaceutical Biotechnology - Comparing National Innovation Systems at the Sectoral Level (link)

April 11, 2006

Paris, 10 Apr 2006

What are the specific characteristics of innovation in pharmaceutical biotechnology? How do biopharmaceutical innovation systems in OECD countries perform and which policies are suitable to foster performance?

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries: Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries' performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process. Major systemic failures affecting the functioning of the biopharmaceutical innovation systems are identified. Based on rich evidence, the report draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

This study forms part of a larger effort to compare innovation processes in different industry sectors and technological fields to provide policy guidance and to more fully elaborate the national innovation systems (NIS) approach to policy making.

Table of contents

Foreword

Executive Summary (English) - available for free download

Note de synthèse (French) - available for free download

  • Chapter 1. Introduction

  • Chapter 2. Summary of Country Studies:
    • Belgium
    • Finland
    • France
    • Germany
    • Japan
    • The Netherlands
    • Norway
    • Spain
  • Chapter 3. Comparison of Performance in National Biopharmaceutical Innovation Systems

  • Chapter 4. Openness of the Biopharmaceutical Innovation System

  • Chapter 5. Comparison of Selected Demand-side Factors

  • Chapter 6. Structure, Dynamics and Performance in National Biopharmaceutical Innovation Systems

  • Chapter 7. Systemic Imperfections in Biopharmaceutical Innovation Systems

  • Chapter 8. Policy Implications
  • The full volume can be browsed on the OECD Online Bookshop.

    Further information

    Organisation for Economic Co-operation and Development
    http://www.oecd.org
    Item source

    You've reached your article limit

    Register to continue

    Registration is free and only takes a moment. Once registered you can read a total of 6 articles each month, plus:

    • Sign up for the editor's highlights
    • Receive World University Rankings news first
    • Get job alerts, shortlist jobs and save job searches
    • Participate in reader discussions and post comments
    Register

    Have your say

    Log in or register to post comments

    Featured Jobs

    Most Commented

    Doctoral study can seem like a 24-7 endeavour, but don't ignore these other opportunities, advise Robert MacIntosh and Kevin O'Gorman

    Matthew Brazier illustration (9 February 2017)

    How do you defeat Nazis and liars? Focus on the people in earshot, says eminent Holocaust scholar Deborah Lipstadt

    Laurel and Hardy sawing a plank of wood

    Working with other academics can be tricky so follow some key rules, say Kevin O'Gorman and Robert MacIntosh

    Improvement, performance, rankings, success

    Phil Baty sets out why the World University Rankings are here to stay – and why that's a good thing

    Warwick vice-chancellor Stuart Croft on why his university reluctantly joined the ‘flawed’ teaching excellence framework